Services-Commercial Physical & Biological Research
17 listed companies the SEC classes under this industry (code 8731), in order of revenue.
17 of them have annual figures on record. The 17 reporting in US dollars had revenue of $36.5B between them in their latest fiscal years.
| Company | Fiscal year to | |||
|---|---|---|---|---|
| Iqvia Holdings Inc. | Dec 2025 | $16.3B | $1.36B | $29.9B |
| Icon plc | Dec 2025 | $8.25B | $229.3M | $16.3B |
| Incyte Corp | Dec 2025 | $5.14B | $1.29B | $6.96B |
| Charles River Laboratories International, Inc. | Dec 2025 | $4.02B | −$144.3M | $7.14B |
| Medpace Holdings, Inc. | Dec 2025 | $2.53B | $451.1M | $1.98B |
| NRC Health | Dec 2025 | $137.4M | $11.6M | $134.9M |
| Maxcyte, Inc. | Dec 2025 | $33.0M | −$44.6M | $202.5M |
| OmniAb, Inc. | Dec 2025 | $18.7M | −$64.8M | $300.9M |
| Foxo Technologies Inc. | Dec 2025 | $16.4M | −$12.4M | $44.6M |
| bioAffinity Technologies, Inc. | Dec 2025 | $6.16M | −$14.9M | $11.0M |
| Absci Corp | Dec 2025 | $2.80M | −$115.2M | $216.3M |
| iSpecimen Inc. | Dec 2025 | $1.93M | −$10.5M | $9.53M |
| OneMedNet Corp | Dec 2025 | $1.36M | −$2.80M | $2.15M |
| Cannabis Bioscience International Holdings, Inc. | May 2025 | $303.0K | −$548.8K | $31.9K |
| IB Acquisition Corp. | Sep 2025 | – | $3.42M | $17.1M |
| Weed, Inc. | Dec 2025 | – | −$1.37M | $559.9K |
| Vitaspring Biomedical Co. Ltd. | Jan 2026 | – | −$415.4K | $14.7K |
Each company's latest fiscal year, as its annual report to the SEC gave the figures; the year links to that report. Amounts in other currencies are not converted, and sort after those in dollars.